Overview

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Treatments:
Apatinib